MGRC Healthcare and De Cell Berhad Embark on Strategic Collaboration to Propel Cell-Gene Therapy Innovations

Unveiling the Future of Biopharmaceuticals with EXOGENETIX   

PETALING JAYA, 17 April 2024 – Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group”), a leading genomics and biopharmaceutical specialist, is pleased to announce that their wholly-owned subsidiary MGRC Healthcare Sdn. Bhd. has entered a Strategic Collaboration Agreement (“SCA”) with De Cell Berhad. This partnership is set to enhance the development and commercialisation of the pioneering EXOGENETIX program, setting new standards in the field of cell-gene therapies.

Under this new strategic alliance, MGRC Healthcare will leverage its vast biopharmaceutical expertise to provide technical and production support, thereby optimising the operational efficiency and market deployment of the EXOGENETIX program. Concurrently, De Cell Berhad will take on the role of the exclusive marketing partner, overseeing all promotional and trademark activities to amplify the program's market presence and success.

This collaboration underscores MGRC’s commitment to spearheading innovation and transforming healthcare outcomes through advanced biotechnologies. By combining MGRC Healthcare's production capabilities with De Cell Berhad's marketing acumen, this partnership is poised to significantly advance the reach and effectiveness of the EXOGENETIX program.

Azri Azerai, Executive Chairman of Malaysian Genomics expressed his enthusiasm for the agreement, "We are thrilled to partner with De Cell Berhad to advance the field of cell-gene therapy. This partnership not only aligns with our strategic vision to deliver cutting-edge healthcare solutions but also reinforces our dedication to pushing the boundaries of medical science."

Dr. Lim Wooi Khai, Director of De Cell Berhad, also commented on the collaboration, "This SCA with MGRC Healthcare represents a significant moment for us at De Cell Berhad. The EXOGENETIX program is a cornerstone of our strategy to bring innovative therapies to the market. Through this partnership, we are set to accelerate the development and delivery of next-generation cell-gene therapies, ultimately improving patient outcomes. We are eager to see the transformative impact this collaboration will have on the healthcare industry."

This collaboration will concentrate MGRC on broadening the scope and effectiveness of the EXOGENETIX program. This strategic alliance aims to support the ongoing evolution of the biopharmaceutical sector by integrating advanced biotechnologies with effective marketing strategies, thereby addressing the increasing needs for sophisticated therapeutic options.